Vol 8, Supp. C (2017)
Case report
Published online: 2017-12-31
Effectiveness of ruxolitinib in the treatment of patients with myelofibrosis with co-morbidities
Abstract
Myelofibrosis (MF) is a heterogenous Philadelphia-myeloproliferative neoplasm that is characterized by bone marrow fibrosis and impaired hematopoiesis. Clinical hallmarks of MF are increased splenomegaly, cytopenias and general symptoms. Deregulation of JAK–STAT signaling pathway plays a key role in the pathogenesis of MF. Ruxolitinib is a selective and oral JAK1/JAK2 inhibitor that in clinical trials demonstrated significant efficacy in the reduction of clinical symptoms, improved the quality of life and increased overall survival of patients with MF.
Keywords: myelofibrosisruxolitinibhepatosplenomegalycomorbidities
References
- Atallah E, Verstovsek S. Emerging drugs for myelofibrosis. Expert Opin Emerg Drugs. 2012; 17(4): 555–570.
- Tefferi A, Thiele J, Vardiman JW. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. Cancer. 2009; 115(17): 3842–3847.
- Rollison DE, Howlader N, Smith MT, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood. 2008; 112(1): 45–52.
- Erf LA, Herbut PA. Primary and secondary myelofibrosis (a clinical and pathological study of thirteen cases of fibrosis of the bone marrow). Ann Intern. 1944; 21(5): 863–889.
- Alshemmari SH, Rajan R, Emadi A. Molecular pathogenesis and clinical significance of driver mutations in primary myelofibrosis: a review. Med Princ Pract. 2016; 25(6): 501–509.
- Mui AL. The role of STATs in proliferation, differentiation, and apoptosis. Cell Mol Life Sci. 1999; 55(12): 1547–1558.
- Hasselbalch HC. Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? Blood. 2012; 119(14): 3219–3225.
- Frederiksen H, Farkas DK, Christiansen CF, et al. Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study. Blood. 2011; 118(25): 6515–6520.
- Hasselbalch HC. Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development? Leuk Res. 2013; 37(2): 214–220.
- Čokić VP, Mitrović-Ajtić O, Beleslin-Čokić BB, et al. Proinflammatory cytokine IL-6 and JAK-STAT signaling pathway in myeloproliferative neoplasms. Mediators Inflamm. 2015; 2015: 453020.
- Alchalby H, Lioznov M, Fritzsche-Friedland U, et al. Circulating CD34(+) cells as prognostic and follow-up marker in patients with myelofibrosis undergoing allo-SCT. Bone Marrow Transplant. 2012; 47(1): 143–145.
- Verstovsek S, Mesa RA, Gotlib J, et al. COMFORT-I investigators. Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis. Postgrad Med. 2013; 125(1): 128–135.
- Burger R, Bugdahn T, Staudinger M, et al. Preclinical activity of the JAK1/2 inhibitor ruxolitinib on malignant plasma cell growth and survival. J Clin Oncol. 2014; 20(2): e18565.
- Harrison CN, Kiladjian JJ, Gisslinger H, et al. Ruxolitinib provides reductions in splenomegaly across subgroups: an analysis of spleen response in the COMFORT-II study. Blood. 2011; 118: 279.
- Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012; 366(9): 787–798.
- Verstovsek S, Mesa RA, Gotlib J. The results of COMFORT-I, a double-blind placebo-controlled Phase III study of ruxolitinib demonstrated the significant benefit of ruxolitinib in reducing spleen size, alleviating symptoms and improving quality of life in patients with MF. N Engl J Med. 2012; 366: 799–807.
- Verstovsek S, Mesa RA, Gotlib J, et al. COMFORT-I investigators. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. J Hematol Oncol. 2017; 10(1): 55.
- Ballen KK, Shrestha S, Sobocinski KA, et al. Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant. 2010; 16(3): 358–367.
- Sacha T. Skuteczność leczenia pierwotnej mielofibrozy inhibitorami kinazy JAK2. Hematologia. 2013; 3: 197–205.
- Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012; 366(9): 787–798.
- Wróbel T. Ruksolitynib w leczeniu nowotworów mieloproliferacyjnych Ph(-). Acta Haematol Pol. 2015; 46(4): 292–298.
- Harrison CN, Vannucchi AM, Kiladjian JJ, et al. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia. 2016; 30(8): 1701–1707.
- Cervantes F, Vannucchi AM, Kiladjian JJ, et al. COMFORT-II investigators. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood. 2013; 122(25): 4047–4053.
- Vannucchi AM, Kantarjian HM, Kiladjian JJ, et al. COMFORT Investigators. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. Haematologica. 2015; 100(9): 1139–1145.